DUBLIN--(BUSINESS WIRE)--The "Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The chronic obstructive pulmonary disease (COPD) drugs market will register a CAGR of almost 4% by 2023.
There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD.
In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution, exposure to second-hand or passive smoking, smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status and dietary factors, which lead directly or indirectly to COPD.
Apart from lifestyle factors, there are factors such as old age and presence of rare genetic disorders, which contribute to the rising prevalence of COPD.
Strong pipeline and new drug approvals
The pipeline for the treatment of COPD includes several drug combinations, which can provide a wide range of therapeutic benefits.
These drug combinations are presently in the late stages of development, with some expected to be launched in the market during the forecast period. These molecules combine the properties of drugs from different classes and have diversified therapeutic mechanisms of action and hence are expected to change the course of COPD treatment.
Low diagnosis rates for COPD
There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD.
Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.
Competitive Landscape
The chronic obstructive pulmonary disease (COPD) drugs market appears to be moderately concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
Key Players
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Novartis
- Teva Pharmaceutical
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Comparison by product
- Combination therapy - Market size and forecast 2018-2023
- Monotherapy - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
- Chronic bronchitis
- Emphysema
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Novartis
- Teva Pharmaceutical
For more information about this report visit https://www.researchandmarkets.com/research/5d4snr/chronic?w=4
